DEF 14A: Psychemedics Corporation Proposes Reverse Stock Split and Deregistration Plan

Psychemedics Corporation is seeking stockholder approval for a reverse stock split, forward stock split, and a stock purchase agreement to deregister its common stock and delist from the Nasdaq.

Summary

• Psychemedics Corporation is holding a virtual annual meeting on November 25, 2024, to vote on several proposals.
• The key proposals involve a reverse stock split (ratio of 1-for-4,000 to 1-for-6,000) followed by a forward stock split at the same inverse ratio.
• If approved, stockholders owning fewer than 4,000-6,000 shares (depending on the board's decision) will receive $2.35 per share in cash and will no longer be stockholders.
• The company also seeks to ratify a stock purchase agreement with Mr. Kamin for up to 1,595,744 shares at $2.35 per share, totaling up to $3,750,000.
• The purpose of these actions is to reduce the number of record holders below 300, allowing the company to deregister its stock under the Securities Exchange Act of 1934 and delist from the Nasdaq.
• The board believes the costs of being a public reporting company outweigh the benefits.
• The board recommends voting FOR all proposals.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company aims to reduce costs and streamline operations, there are potential downsides for stockholders, including reduced information and liquidity. The increased control by Mr. Kamin also introduces a potential conflict of interest.

Positives

• The company expects to save approximately $845,000 annually by deregistering and delisting.
• Small stockholders will have the opportunity to liquidate their holdings at $2.35 per share without brokerage commissions.
• Management will have more time to focus on operations instead of compliance.
• The company intends to continue preparing audited annual financial statements and make them available to stockholders.

Negatives

• Cashed-out stockholders will no longer have any ownership interest in the company.
• Continuing stockholders will have significantly less information about the company.
• The company will no longer be listed on the Nasdaq Capital Market, potentially decreasing liquidity.
• The company will no longer be subject to Sarbanes-Oxley Act provisions.
• The cost of the transaction is estimated at approximately $3,692,947.
• Continuing stockholders will have less influence due to Mr. Kamin's increased ownership and director designation rights.

Risks

• The board may abandon the transaction even if approved by stockholders.
• The company's public reporting obligations could be reinstated if the number of record holders exceeds 300 in the future.
• Continuing stockholders may experience a significant decrease in the value of their common stock due to limited liquidity and reduced information.
• There is no assurance that any trading market will emerge following the deregistration and delisting of our common stock, or, if it does, how long it might last.

Future Outlook

The company intends to delist from Nasdaq and deregister under the Exchange Act, ceasing SEC reporting obligations. They will continue to prepare audited annual financial statements and make them available to stockholders.

Management Comments

• The Board and the Transaction Committee have determined that the costs of being an SEC reporting company outweigh the benefits.
• The Board decision to approve the proposed going dark transaction and its specific terms was the result of an independent and rigorous process to determine the best course for all the Company's stockholders.

Industry Context

The document notes that the clinical laboratory industry is intensely competitive, with many competitors being larger and able to offer lower pricing due to scale. This context supports the company's rationale for seeking cost reductions through deregistration.

Comparison to Industry Standards

• The document compares Psychemedics to other companies in the laboratory services, testing, and diagnostics industries, including Labcorp, Quest Diagnostics, and Eurofins Scientific.
• These companies have significantly larger market capitalizations and revenues than Psychemedics.
• The document also references precedent transactions in the industry, such as the acquisition of LifeLabs by Quest Diagnostics and Ortho Clinical Diagnostics by Quidel Corporation, to assess the fairness of the proposed transaction.

Related Party Transactions

• The Stock Purchase Agreement with Mr. Kamin and affiliated entities is a related party transaction.
• Mr. Kamin's increased beneficial ownership and director designation rights create a potential conflict of interest.

Stakeholder Impact

• Stockholders owning fewer than 4,000-6,000 shares will be cashed out and will no longer have an ownership stake in the company.
• Continuing stockholders will have less information and potentially reduced liquidity.
• Management will have more time to focus on operations.
• The company will no longer be subject to the same level of regulatory oversight.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on November 25, 2024.
• If approved, the company will file the necessary documents with the SEC to deregister its stock and delist from Nasdaq.
• The company will then implement the reverse and forward stock splits and pay cash to stockholders owning fewer than 4,000-6,000 shares.

Key Dates

Keywords

reverse stock split, deregistration, delisting, stock purchase agreement, going dark, proxy statement, Kamin, Psychemedics, stockholders